Clinical Trial Update: Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD) [Phase 2]

View source ↗

Summary

Clinical trial update for NASPOCAD, a Phase 2 study evaluating niacin for secondary prevention of coronary artery disease. The current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Niacin (nicotinic acid)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Coronary Artery Disease | Phase 2 | Status: UNKNOWN